11月17日 - ** 在澳大利亚证券交易所上市的炎症性疾病药物生产商Mesoblast MSB.AX的股价上涨3.6%，达到2.3澳元，结束了连续两个交易日的下跌。
** 公司任命 (link) James O'Brien 为驻美国首席财务官
** 吉姆最近担任过的首席财务官职务包括在纳斯达克上市的生物制药公司 Cognition Therapeutics Inc CGTX.O，成功监督了首次公开募股等。
** 在基准 S&P/ASX 200 指数.AXJO中，该股涨幅排名第四
** 截至格林尼治标准时间 0104 时，股价上涨 2.7%，报 2.28 澳元
** 今年以来股价下跌26.5%，包括当天的走势
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.